In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ischemia Technologies raises $10.3mm in Series B financing

Executive Summary

Ischemia Technologies (diagnostic medical devices focusing on ischemia) has grossed $10.3mm in a Series B financing of preferred stock. Initially the company had raised $6.8mm in November through the round, which was led by new investors Wolf Ventures and Murphree Ventures. Crawley Venture Group, also new, participated along with current investors Sequel Venture Partners, Quest Capital, and Roser Ventures and Piedmont Venture Partners. In December White Pines Ventures, Tenex Medical, and a European investor added another $3.5mm.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies